Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

G Protein-coupled Receptors

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multiparametric MRI assessment of acute neuroinflammation in a murine model of peripheral LPS stimulation.

BMC medical imaging·2025

Same author

Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study.

The Journal of clinical psychiatry·2025

Same author

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.

Science translational medicine·2025

Same author

Characterization of a Clinically and Biologically Defined Subgroup of Patients with Autism Spectrum Disorder and Identification of a Tailored Combination Treatment.

Biomedicines·2024

Same author

Understanding the patient and supporter journey in cocaine use disorder.

Frontiers in psychiatry·2024

Same author

Patient perspectives on current and potential therapies and clinical trial approaches for cocaine use disorder.

Frontiers in psychiatry·2024

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

A Kinetic Fluorescence-based Ca²⁺ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

mGluR5 antagonists: discovery, characterization and drug development.

Fabrizio Gasparini¹, Graeme Bilbe, Baltazar Gomez-Mancilla

¹Novartis Pharma AG, Novartis Institutes for BioMedical Research Basel, Neurosciences Discovery, Basel, Switzerland. fabrizio.gasparini@novartis.com

Current Opinion in Drug Discovery & Development

|August 30, 2008

Summary

Targeting metabotropic glutamate receptor 5 (mGluR5) antagonists offers a promising therapeutic strategy for nervous system disorders. These allosteric modulators show potential where ionotropic glutamate receptor blockers failed due to limited therapeutic windows.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Related Experiment Videos

Last Updated: Jul 2, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

A Kinetic Fluorescence-based Ca²⁺ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Area of Science:

Neuroscience
Pharmacology
Neurobiology

Background:

Glutamate neurotransmission is crucial for nervous system function.
Dysregulation of glutamate pathways is linked to various neurological disorders.
Previous attempts using ionotropic glutamate receptor blockers faced challenges with therapeutic windows.

Purpose of the Study:

To explore the therapeutic potential of targeting metabotropic glutamate receptors (mGluRs).
To summarize the identification and characterization of mGluR5 antagonists.
To review recent clinical development progress for mGluR5 antagonists.

Main Methods:

Review of scientific literature on glutamate receptor pharmacology.
Analysis of preclinical validation studies for glutamate receptor modulators.
Examination of clinical trial data for mGluR5 antagonists.

Main Results:

Metabotropic glutamate receptors (mGluRs) offer a novel approach to modulate glutamatergic transmission.
Selective allosteric antagonists of the mGluR5 subtype have shown significant therapeutic promise.
Recent advancements indicate progress in the clinical development of these agents.

Conclusions:

mGluR5 antagonists represent a promising therapeutic avenue for neurological conditions.
The modulatory role of mGluRs provides a viable alternative to direct ionotropic receptor blockade.
Ongoing clinical development highlights the potential of mGluR5-targeted therapies.